Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P06681
UPID:
CO2_HUMAN
Alternative names:
C3/C5 convertase
Alternative UPACC:
P06681; B4DPF3; B4DV20; E9PFN7; O19694; Q13904
Background:
Complement C2, a pivotal protein in the classical pathway of the complement system, is cleaved into C2b and C2a fragments by activated factor C1. C2a, a serine protease, then combines with C4b to form the C3 or C5 convertase, crucial for immune response.
Therapeutic significance:
Complement C2 is linked to age-related macular degeneration (AMD) and complement component 2 deficiency, affecting vision and immune function. Understanding its role could lead to novel treatments for these conditions.